Shilpa Medicare has received an approval from the United States Food & Drug Administration (USFDA) (the Office of Bioequivalence) for Capecitabine Tablets USP, 150 mg and 500 mg to be bioequivalent and therapeutically equivalent to the reference listed drug product (RLD), Xeloda Tablets, 150 mg and 500 mg of Hoffmann-La Roche, Inc.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
